European regulators blocked Illumina’s $8 billion acquisition of Grail on Tuesday, dealing a whiplash blow to the biotech just days after it prevailed over an FTC challenge.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,